Ironwood Pharmaceuticals (IRWD) Status Update summary

Strategic Vision and Restructuring

• Focus is shifting to apraglutide for short bowel syndrome, with a rolling NDA submission now expected in Q3 2025 to include robust long-term data from the STARS Extend study.

• Workforce reduction of approximately 50%, mainly impacting the field force, aims to streamline operations and support the apraglutide launch, with restructuring charges of $20–$25 million and annual operating expense savings of $55–$60 million.

• Reorganization includes winding down the STARGAZE Phase 2 study in Graft-versus-Host Disease to concentrate resources on apraglutide.

• Commercial strategy for apraglutide targets a smaller, specialized prescriber base, focusing on academic centers and patient hub services.

• Leadership changes include Greg Martini as SVP, CFO, and Tammi Gaskins as SVP, Chief Commercial Officer.

Apraglutide Development and Data

• Rolling NDA submission for apraglutide includes new long-term extension data, with 27 patients achieving enteral autonomy and increased rates of weaning off parenteral support.

• Ongoing constructive dialogue with FDA, leveraging fast-track designation to optimize submission and labeling.

• Launch planning for apraglutide is underway, emphasizing a robust patient hub service model.

Financial Guidance and Performance

• FY2025 guidance: LINZESS U.S. net sales of $800–$850 million, total revenue of $260–$290 million, and adjusted EBITDA over $85 million, with a $40–$45 million net benefit from reorganization.

• High single-digit prescription growth for LINZESS is expected, but more than offset by price erosion from Medicare Part D redesign and Medicaid AMP cap repeal.

• Adjusted EBITDA definition updated to exclude stock-based compensation starting Q1 2025.

• R&D spend anticipated to decline slightly in 2025 due to winding down of certain operations and completion of apraglutide phase III.